Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia

Cançado, Rodolfo Delfini; Figueiredo, Pedro Otavio Novis de; Olivato, Maria Cristina Albe; Chiattone, Carlos S.

doi:10.5581/1516-8484.20110119

Cited by 20 publications

(22 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, though only 5.53% severely anemic pregnant women became nonanemic, but as a group, they reached a mean Hb level that was likely to protect them from the adverse consequences of anemia during pregnancy. We again revert back to the moot question as to whether total iron dose calculation based on Ganzoni's formula[ 35 ] and consequent administration of much higher dose of IVIS would have resulted in much improved endline Hb status, particularly among severely anemic pregnant women? [ 35 36 ] Intuitively, it does appear to be so but would require further careful exploration.…”

Section: Discussionmentioning

confidence: 99%

Effect of intravenous iron sucrose on hemoglobin level, when administered in a standard-dose, to anemic pregnant women in rural Northern India

Haldar

Kant

Yadav

et al. 2018

J Family Med Prim Care

View full text Add to dashboard Cite

Introduction:To combat anemia among pregnant women, in Haryana, Northern India, administration of intravenous iron sucrose (IVIS) was initiated in 2014 as a public-health measure. We assessed the effect of IVIS on hemoglobin (Hb) levels among the pregnant anemic women.Methods:Pregnant women identified as moderately or severely anemic (Hb <10.0 g/dL) in the second or third trimester during routine antenatal care were prescribed IVIS in a standard-dose of 400 mg given as 100 mg on alternate days. Neither dose calculation, nor allowance for iron-store, was included in this study. We analyzed the data collected between June 2014 and December 2015, at the two primary-health-centers, on Hb level (by HemoCue method) before start of the therapy (baseline), and 4-week or more after the last infusion (endline).Results:A total of 990 women received IVIS. Both baseline and endline Hg-levels were available for 763 (77%), who were included in the analysis. At baseline, the proportion of moderate and severe anemia was 87.94% and 12.06%, respectively. Mean (standard deviation)-Hb increased from 7.85 g/dL (0.80) at baseline, to 9.62 g/dL (1.30) at endline, with a mean increase of 1.76 g/dL (95% confidence interval 1.67, 1.85). The mean increase in Hb-level for pregnant women who had severe and moderate anemia at baseline was 2.54 g/dL and 1.65 g/dL, respectively. Overall, 15.33% of women achieved normal Hb-level by the time of endline measurement. No serious adverse reactions were reported during the observation period.Conclusion:Mean increase in Hb-level was 1.76 mg/dL. Severely anemic pregnant women had larger increase in Hb-level when compared with pregnant women with moderate anemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of intravenous iron sucrose on hemoglobin level, when administered in a standard-dose, to anemic pregnant women in rural Northern India

Haldar

Kant

Yadav

et al. 2018

J Family Med Prim Care

View full text Add to dashboard Cite

show abstract

“…5 Parental iron preparations also available in the past, were associated with serious life threatening anaphylactic reactions that may result to death. 6 Modern alternative strategies call for parentral administration of new, well tolerated iron preparation e.g., iron sucrose which has been successfully used in the treatment of postpartum anaemia and increasingly during 2nd and 3rd trimester of pregnancy. 5 This study was done to find out the efficacy and safety of intravenous iron sucrose in the treatment of iron deficiency anaemia in the postpartum period.…”

mentioning

confidence: 99%

Study of effectiveness, tolerability and safety of intravenous iron sucrose in iron deficiency anaemia in postnatal women

Niranjana

Rajeswari²

2018

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Iron deficiency anaemia is the most common type of reversible anemia encountered during pregnancy and postpartum period. The present study was done with the objective to find out the efficacy and safety of intravenous iron sucrose in the treatment of iron deficiency anaemia in the postpartum period.Methods: Fifty (50) postnatal patients both after vaginal and caesarean section with iron deficiency anaemia within the first 48 hours with haemoglobin percentage between 6 g/dl and 8g/dl were studied prospectively at the Institute of Obstetrics and Gynaecology, Madras Medical College, Chennai. The patients were given 100 mg of elemental iron diluted in 100 ml of 0.9% normal saline and infused over 15 minutes every alternate day (not more than 3 days in a week) until the required dosage is infused. The blood samples of all the patients were collected and analyzed for haemoglobin (g/dl), hematocrit, mean corpuscular volume (MCV), serum iron, total iron binding capacity (TIBC) and compared before and after therapy.Results: The mean age group of the patients was 24.94 years. Majority of the patients were multipara (68%) and belongs to the class V socio economic status (84%). All the blood parameters were increased significantly (p=0.000) when compared from baseline values to end of the treatment. Mean raise in haemoglobin% after 30 days of treatment was 3.60. Average raise in the mean hematocrit was 8.73. The mean difference in the mean corpuscular volume, total iron binding capacity and the percent saturation was 129.77, 13.55, was 22.26 respectively.Conclusions: Our data confirm that the intravenous iron sucrose was very effective, well tolerated and safe than other forms of iron preparations for treating iron deficiency anaemia in postnatal women.

show abstract

“…17,18 Parenteral iron preparations which were available in the olden days were associated with dangerous complications like anaphylactic reactions and death, due to which they have gone in disrepute. 19 The high-molecular-weight iron dextran formulation most frequently were responsible for these side effects seen in 2.3% of the patients. 20,21 However, the availability of new preparations like iron sucrose, with much better safety profiles, are more useful in day to day clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Intravenous iron sucrose for treatment of anemia in gynecology patients awaiting surgery

Gandhi

Satia

2016

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Anemia refers to reduction in the total circulatory erythrocyte mass which results in decrease in the oxygen carrying capacity of the blood. Patients who require a surgical intervention as regards their complaints are many a times denied fitness because of anemia. Current anesthetic and surgical practice ideally recommend a hemoglobin level of > 10 g/dl or a hematocrit of >30 % for any surgical intervention. Surgery is postponed until cause of anemia is identified and the anemia corrected without resorting to blood transfusions. The current study evaluates other alternatives to increase the hemoglobin as early as possible without resorting to blood transfusion. The efficacy and safety of intravenous iron sucrose along with the achievement of the desired hemoglobin values for patients posted for elective gynecological surgeries within the next menstrual cycle was evaluated. Methods: This study was an open label, single arm, and prospective study of women with iron deficiency anemia in gynecological disorders. 100 patients attending Gynecology OPD of Seth G. S. Medical College and KEM Hospital, Parel, Mumbai, Maharashtra, India requiring surgical intervention but not given fitness due to anaemia were the subjects of this study. All patients with surgically treatable conditions with hemoglobin level >7g/dL but < 10 g/dl were the inclusion criteria Selected subjects received intravenous iron sucrose. Maximum dose 200mg/weekX3 weeks initially. At the end of three weeks of starting therapy Hb estimation was done and compared with the baseline levels as regarding the hemoglobin rise. The results were statistically analyzed using the "paired t" test. Results: The requirement of iron-sucrose for the individual patient was calculated based on the weight of the patient. The analysis of iron requirement-sucrose combination showed a mean of 481.7 mg with standard deviation (SD) of 62.72 mg and a range of 378.85 mg. The minimum iron-sucrose requirement was 361.55 mg and the maximum was 740.40 mg The mean Hb (gm%) value before intervention was 8.43 with a standard deviation of 0.56, whereas, the mean Hb (gm %) value after intervention was higher, 10.41 with standard deviation (SD) of .56 the mean Hb (gm %) Increase in 2 weeks was 1.60 with standard deviation (SD) of 0.31, whereas, in 3 weeks was 2.03 with standard deviation (SD) of 0.51. The mean Hb (gm %) increase was higher in participants with 3 weeks, which was statistically significant (p<0.05). Conclusions: Parenteral iron therapy was not safe in the past but iron sucrose has made it the safest and effective therapy. Parenteral iron therapy can be used for patients with Hb level between 6-8mg/dl It is highly efficacious and reliable way to achieve the desired Hb level patient compliance is assured with intravenous iron sucrose patient can be satisfactorily posted for surgery within a period of 3 weeks i.e. within her next menstrual period by reliably and effectively correcting her anemia with intravenous iron sucrose.

show abstract

Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia

Cited by 20 publications

References 24 publications

Effect of intravenous iron sucrose on hemoglobin level, when administered in a standard-dose, to anemic pregnant women in rural Northern India

Effect of intravenous iron sucrose on hemoglobin level, when administered in a standard-dose, to anemic pregnant women in rural Northern India

Study of effectiveness, tolerability and safety of intravenous iron sucrose in iron deficiency anaemia in postnatal women

Intravenous iron sucrose for treatment of anemia in gynecology patients awaiting surgery

Contact Info

Product

Resources

About